Galera Therapeutics (GRTX) just unveiled an announcement.
Galera Therapeutics, Inc. recently settled a lawsuit against two Clinical Research Organizations (CROs) for a sum of $975,000. The dispute centered around a 2021 error in a pivotal Phase 3 cancer trial, which prompted allegations of contract breach and negligence from Galera. With the settlement, both parties have released each other from further obligations and plan to formally conclude the litigation by August 2024.
For detailed information about GRTX stock, go to TipRanks’ Stock Analysis page.
